Solid Biosciences and Stoke Therapeutics Get Fresh Bullish Analyst Backing with Big Upside Targets
Truist restarts Solid Biosciences at Buy/$20. JPMorgan backs Stoke Therapeutics at Overweight/$40. Cash into 2028.
/ 4 items
#STOK↓
Goldman Sachs Initiates Coverage on Stoke Therapeutics with Buy Rating and $44 Price Target
The firm sees strong potential for zorevunersen in treating Dravet syndrome.
Guggenheim Starts Coverage on Stoke Therapeutics with Buy Rating and $60 Target
Guggenheim initiates coverage on Stoke Therapeutics, highlighting Zorevunersen’s potential as a disease-modifying treatment for Dravet syndrome and projecting $2.5B peak sales.
FDA Requests Additional Data on Stoke's Dravet Syndrome Treatment
Stoke Therapeutics continues discussions with FDA for expedited approval of zorevunersen for Dravet syndrome after regulators request more information on the epilepsy treatment.